Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire, New River Submit NDA For Amphetamine Prodrug NRP104

This article was originally published in The Pink Sheet Daily

Executive Summary

Firms say lower abuse liability is potential advantage over other stimulant attention deficit/hyperactivity disorder treatments.
Advertisement

Related Content

Shire Anticipates Vyvanse Approval In “Next Month Or Two”
Shire Anticipates Vyvanse Approval In “Next Month Or Two”
Shire Settlement With Barr Permits Generic Adderall XR Entry In 2009
Shire Settlement With Barr Permits Generic Adderall XR Entry In 2009
New River To Co-Promote ADHD Drug With Shire
New River To Co-Promote ADHD Drug With Shire
Shire Aims For Four Launches By Year-End
Shire Aims For Four Launches By Year-End

Topics

Advertisement
UsernamePublicRestriction

Register

PS061485

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel